Home Sectors Healthcare Stock to Track: Spectrum Pharmaceuticals (NASDAQ: SPPI)

Stock to Track: Spectrum Pharmaceuticals (NASDAQ: SPPI)


Spectrum Pharmaceuticals trades as part of the biotechnology industry and is part of the healthcare sector. The company CEO is Joseph W. Turgeon. Spectrum Pharmaceuticals Inc is a biotechnology company in the United States. It develops drugs to cure serious diseases such as chemotherapy-induced neutropenia in patients with breast cancer.

Previous Intraday Trading Performance:

The SPPI stock showed a previous change of 2.00% with an open at 7.55 and a close of 7.65. It reached an intraday high of 7.72 and a low of 7.52.

Business Wire:  Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting


The stock has a market cap of $856.5m with 112.0m shares outstanding, of which the float is 109.5m shares. Trading volume reached 804,911 shares compared to its average volume of 796,642 shares. Based on the current average volume and close price, the trading liquidity is bad, highly speculative and an investor may want to avoid this stock.

Historical Trading Performance:

Over the last five trading days, Spectrum Pharmaceuticals shares returned -4.14% and in the past 30 trading days it returned -17.74%. Over three months, it changed -26.51%. In one year it has changed -61.54% and within that year its 52-week high was 25.29 and its 52-week low was 6.22. SPPI stock is 22.99% above its 52 Week Low.

Our calculations show a 200 day moving average of 12.24 and a 50 day moving average of 9.02. Currently SPPI stock is trading -37.48% below its 200 day moving average and may not be a good opportunity to buy as it may continue to trend down.

Business Wire:  Spectrum Pharmaceuticals Announces Integrated Results from Two Phase 3 ROLONTIS® (eflapegrastim) Trials Being Presented at the ASCO Annual Meeting


The last annual fiscal EPS for the company was reported at -1.16 that ended on 31st of December 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -0.27. The TTM EPS is -0.94.

Below was the last reported quarterly diluted earnings per share:

1stQtr of 2019 (Reported on 05/09/2019): -0.17
4thQtr of 2018 (Reported on 02/28/2019): -0.47
3rdQtr of 2018 (Reported on 11/08/2018): -0.66
2ndQtr of 2018 (Reported on 08/09/2018): 0.13
1stQtr of 2018 (Reported on 05/03/2018): -0.16

Base on our calculations, the intrinsic value per share is 81.30, which means it is possibly undervalued and has a margin of safety of 90.59%.

Indicators to Watch:

The current calculated beta is 2.55.

SeekingAlpha:  Retail REITs: Fears Of Retail Apocalypse 2.0

Fundamental Indicators:

Based on last reported financials, the company’s return on equity is -43.44%, return on assets is -32.57%, price-to-sales is 10.65 and price-to-book is 3.08.

Company Scores:

All scores are out of six:
 2  :Valuation Score
 0  :Past Performance Score
 6  :Financial Strength Score
 5  :Future Growth Score
 0  :Dividend Score
 3  :Overall Score

John Jones
Worked for several Wall Street firms: Salomon Smith Barney, UBS, and Charles Schwab. Has developed skills and gained extensive experience over the years that is used today to uncover winning penny stocks.Also was an attorney for small businesses in Scottsdale, Arizona. That experience and understanding of law provides a unique perspective and edge in discovering quality companies in various industries.